Compile Data Set for Download or QSAR
Report error Found 92 Enz. Inhib. hit(s) with Target = 'Apoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide'
TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571527BDBM571527((rac)-(rac-15)-benzyl-4-chloro-3-ethyl-7-{3-[(6-fl...)
Affinity DataIC50: 1.22E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571495BDBM571495((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.32E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571496BDBM571496((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.41E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571472BDBM571472((−)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{...)
Affinity DataIC50: 1.46E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571475BDBM571475((+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluor...)
Affinity DataIC50: 1.51E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571488BDBM571488((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.59E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571469BDBM571469((+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-...)
Affinity DataIC50: 1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571474BDBM571474((rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[...)
Affinity DataIC50: 1.63E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572222BDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571489BDBM571489((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 1.70E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571470BDBM571470((−)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphtha...)
Affinity DataIC50: 1.78E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571477BDBM571477((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.81E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571476BDBM571476((−)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6...)
Affinity DataIC50: 1.83E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571463BDBM571463((rac)-4-Chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-...)
Affinity DataIC50: 1.86E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572202BDBM572202(US11478451, Example 086 | (rac)-4-chloro-12,12-dif...)
Affinity DataIC50: 1.88E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572219BDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572219BDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571479BDBM571479((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 1.93E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571510BDBM571510((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 1.96E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571440BDBM571440(US11440923, Example 5 | (rac)-2,3-dimethyl-15-[2-(...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572159BDBM572159((+)-4-chloro-2,3,14-trimethyl-7-[3-(naphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571486BDBM571486((+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571443BDBM571443(US11440923, Example 9 | US11440923, Example 8 | (r...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571487BDBM571487((−)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571443BDBM571443(US11440923, Example 9 | US11440923, Example 8 | (r...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572161BDBM572161(US11478451, Example 16 | US11447504, Example 16 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572162BDBM572162(US11478451, Example 17 | (+)-4-chloro-7-{3-[(6-flu...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572165BDBM572165((rac)-(11 Z)-4-chloro-3-ethyl-2-methyl-7-[3-(napht...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571446BDBM571446((rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571490BDBM571490((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572148BDBM572148(US11478451, Example 1 | (rac)-(11Z)-4-chloro-1,3-d...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571480BDBM571480((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572219BDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571482BDBM571482((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572222BDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571481BDBM571481((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572149BDBM572149(US11478451, Example 4 | rac-4-chloro-1,3-dimethyl-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571483BDBM571483((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572222BDBM572222(US11447504, Example 79 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571437BDBM571437((rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)pr...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571437BDBM571437((rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)pr...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572152BDBM572152(US11478451, Example 7 | (rac)-4-chloro-3-ethyl-7-{...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571437BDBM571437((rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)pr...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571485BDBM571485((rac)-3-Ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572155BDBM572155((rac)-4-chloro-3-ethyl-1-[2-(morpholin-4-yl)ethyl]...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571452BDBM571452(US11440923, Example 17 | US11440923, Example 18 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571452BDBM571452(US11440923, Example 17 | US11440923, Example 18 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571498BDBM571498((−)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthal...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 572175BDBM572175(US11478451, Example 28 | (rac)-12-chloro-10,11-dim...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 571455BDBM571455((rac)-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
US Patent

Displayed 1 to 50 (of 92 total ) | Next | Last >>
Jump to: